Drug search by name

Olodaterol and tiotropium and Renal dysfunction

Generic Name: olodaterol / tiotropium
Dosage Forms: n.a.
Other Brand Names: Stiolto Respimat 28 ACT , Stiolto Respimat 60 ACT , Stiolto Respimat 10 ACT, Stiolto Respimat

Result of checking the interaction of drug Olodaterol and tiotropium and disease Renal dysfunction for safety when used together.

Check result:

Olodaterol and tiotropium <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Tiotropium is primarily eliminated unchanged by the kidney. Renal impairment has been associated with increased plasma drug concentrations and reduced drug clearance after both intravenous infusion and dry powder inhalation. Mild renal impairment (CrCl 50 to 80 mL/min), which is often seen in elderly patients, increased tiotropium systemic exposure (AUC) by 39% following intravenous infusion. In COPD patients with moderate to severe renal impairment (CrCl < or equals to 50 mL/min), tiotropium AUC increased 82% following intravenous administration, which was confirmed by plasma concentrations after dry powder inhalation. Although generally well tolerated, therapy with ipratropium should be administered cautiously in patients with moderate to severe renal impairment. Monitoring for renal function is recommended. Patients should be advised of and monitored for potentially increased systemic adverse effects such urinary retention.

References: